双热响应型微针贴片,通过按需释放药物和主动温度管理加速糖尿病伤口愈合
Dan Xia1, Yumeng Wu2, Ruodan Xu3
1Tianjin Key Laboratory of Materials Laminating Fabrication and Interface Control Technology, School of Materials Science and Engineering, Hebei University of Technology, Tianjin, 300130, China. xiad@hebut.edu.cn.
Journal of nanobiotechnology
|February 14, 2026
概括
一种新型的双热响应型微针贴片 (DTMN) 能够为糖尿病足 (DFU) 提供药物. 这种创新系统增强了伤口愈合和抗击感染,提供了一个有前途的新治疗策略.
科学领域:
- 生物材料科学 生物材料科学
- 再生医学是一种再生医学.
- 纳米技术 纳米技术
背景情况:
- 糖尿病足 (DFU) 存在重大风险,包括截肢和死亡率,通常由感染和高温阻碍愈合而加剧.
- 对于DFU的传统微针 (MN) 疗法由于药物释放缓慢和效率低而面临局限性.
- 开发先进的药物输送系统对于有效的DFU管理至关重要.
研究的目的:
- 开发和评估一种双热响应的微针贴片 (DTMN),用于增强糖尿病足治疗.
- 调查温度诱导的药物释放动力学和DTMN的伤口冷却能力.
- 评估DTMN系统的抗菌,抗氧化和伤口愈合功效.
主要方法:
- 制造具有不同层次的DTMN贴片:SA-PNIPAM/SOS内层用于加速药物释放,PEG-PLGA/尿素外层用于控制释放和冷却,PCL/CS/TH/SOS纳米纤维膜用于抗菌作用.
- 在24小时内评估药物释放概况 (SOS和尿素衍生氨).
- 评估抗氧化活性,抗菌性能,生物相容性和体内伤口愈合效果.
主要成果:
- 该DTMN贴片显示药物释放效率高,在24小时内释放了85.23%的SOS和35.44%的尿素衍生氨.
- 该系统表现出显著的抗氧化活性和强大的抗菌性能对伤口病原体.
- 在实验模型中,DTMN显示出极好的生物相容性,并显著增强了糖尿病足的愈合.
结论:
- 开发的DTMN补丁代表了一个新的,多功能系统,用于DFU管理中的积极和受控的药物输送.
- 这种创新的微针技术提供了一个有前途的治疗策略,以改善愈合结果并减少与糖尿病足相关的并发症.
- 由于DTMN能够结合加速药物输送,伤口冷却和抗菌性质,因此解决了DFU治疗的关键挑战.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
17
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
17
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
18
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
18
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
01:30Modified-Release Drug Delivery Systems: Bioavailability
16
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
16
01:19Modified-Release Drug Delivery Systems: Overview
17
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
17